Immune System Therapeutics initiates Ph I trial of MM drug

Australian drug developer Immune System Therapeutics has launched a trial to test its investigational antibody drug for terminal blood  cancers. The Phase I study in patients with multiple myeloma has, to  date, dosed six subjects. Results so far indicate that the agent is well  tolerated and final results are expected later this year. The  Sydney-based company is seeking to enroll another nine MM patients with  the kappa form of the disease, to be treated over the next few months.